ResoFus Alomar technology state

While focused ultrasound is currently in the early stages of development and adoption, it has the potential to transform the treatment of a variety of serious medical conditions.

All indicators point toward the evolution of this platform technology into a robust medical field, with the pace of research and development, publications, patient treatments and the number of device manufacturers all increasing rapidly in the past few years.

Research, Development, and Commercialization

Some applications of the technology are approved for commercial use and are available in medical treatment centers around the world.  Other uses are still undergoing research, with opportunities for patients to participate in clinical trials at leading medical research institutions.  Even more potential uses of the technology are in the early stages of technical research.

ResoFus Alomar is performing treatments for the following disease: Essential Tremor, Parkinson’s disease, Facet joint syndrome, Bone tumor and metastasis, uterine fibroids and adenomyosis.

The following charts summarize the state of research and regulatory approval of focused ultrasound for nearly 50 medical conditions around the globe.

STATUS BY DISEASE CATEGORY

STATUS BY DEVELOPMENT STAGE

Medical Literature and Scientific Exchange

The volume of peer-reviewed publications on focused ultrasound research has been increasing exponentially in the last 10 years, with over 400 articles published in 2013. In addition, the number of citations in the literature has also increased dramatically, with nearly 12,000 in 2014.

SCIENTIFIC EXCHANGE

The number of papers presented at scientific meetings has been on the rise, particularly with conferences that are dedicated to focused ultrasound.

Expanding Industry

There are currently 28 companies located around the globe that are dedicated to the research and manufacturing of focused ultrasound systems with a range of guidance systems and specialization. This innovative industry is very young, with only five established by the year 2000 and the remaining established by 2014.

Global Adoption

There are nearly 400 commercial focused ultrasound treatment sites around the globe, with a majority in Europe.

COMMERCIAL SITES BY REGION

RESEARCH SITES BY REGION

PATIENTS TREATED

There have been more than 89,000 patients treated with focused ultrasound.  A majority of patients treated have had prostate cancer, followed by uterine fibroids and liver cancer.

CLINICAL INDICATIONS

The number of diseases treated by focused ultrasound has increased from just a couple of conditions before the 1990s to more than 30 in 2014, and several others are expected to be available in the near future.

ResoFus Technology overview
Thermal ablation and mechanical destruction